Skip to main content
BEAM logo

BEAM · Beam Therapeutics Inc. · Webcasts, Transcripts & Audio

Track BEAM — free
$20.90 -0.04 (-0.19%) At close · Nov 20 Play latest call Q4 2025 earnings call transcript
Market Cap
$2.16B
Shares
103.50M
Volume · Nov 20 3.89M Avg daily vol (3M) 2.05M

Beam Therapeutics Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Beam Therapeutics Inc. (BEAM), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Conference
Investor event
2026-12-02
Beam Therapeutics Inc. (BEAM) December 2, 2026 Conference
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-11-18
Beam Therapeutics Inc. (BEAM) November 18, 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-11-17
Beam Therapeutics Inc. (BEAM) November 17, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q3
2026-10-27
Beam Therapeutics Inc. (BEAM) Q3 2026 Earnings Call
Revenue
$307,000
▼ 96.8% YoY
Diluted EPS
$-1.28
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-09-09
Beam Therapeutics Inc. (BEAM) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-08
Beam Therapeutics Inc. (BEAM) September 8, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-05-20
Beam Therapeutics Inc. (BEAM) May 20, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-02-24
Beam Therapeutics Inc. (BEAM) Q4 2025 Earnings Call Transcript
Confident tone New PKU program (BEAM-304) Sickle cell disease program Platform and predictability
Revenue
$114.11M*
▲ 279.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-05
Beam Therapeutics Inc. (BEAM) Q3 2024 Earnings Call Transcript
Confident tone BEAM-101 / BEACON Phase 1/2 in sickle cell disease ESCAPE antibody-based conditioning platform BEAM-302 in alpha-1 antitrypsin deficiency (AATD)
Revenue
$14.27M
▼ 17% YoY
Diluted EPS
$-1.17
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-01-10
Beam Therapeutics Inc. (BEAM) Q4 2021 Earnings Call
Revenue
$51.07M*
▲ 851050% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-10
Beam Therapeutics Inc. (BEAM) Q3 2020 Earnings Call
Revenue
$6,000
▲ 0% YoY
Diluted EPS
$-0.69
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–11 of 11 webcasts
Key facts CIK 1745999 CUSIP 07373V105 13F (30d) 270 filings 247 filers Visit website Investor relations